trending Market Intelligence /marketintelligence/en/news-insights/trending/b9iowrixskddssvvohud0g2 content esgSubNav
In This List

AbbVie's Humira leads 2017 drug sales; House rejects 'right-to-try'

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


AbbVie's Humira leads 2017 drug sales; House rejects 'right-to-try'

Here are the editors' top picks for the week ended March 16.

AbbVie blockbuster leads 2017 top drug sales; Roche cancer meds follow closely

Although three Roche Holding AG cancer drugs were among the top revenue drivers across large pharmaceutical companies in 2017, immunology medicines such as AbbVie Inc.'s Humira still led big companies' drug sales in the year.

House rejects Trump-backed 'right-to-try' experimental drugs bill

Legislation failed to garner enough votes in the House to give critically ill patients greater access to experimental drugs beyond the U.S. Food and Drug Administration's compassionate-use process, dealing a blow to the Republicans who backed the measure.

House moves fast on 2nd push for 'right-to-try' experimental drugs bill

House Republican leaders have set a March 19 hearing for the so-called right-to-try legislation at the Rules Committee, hoping the second attempt at advancing the legislation will yield a win.

Heartbeat-tracking patch from iRhythm may spot signs of stroke risk: study

The U.S. company's wearable patch has the potential to detect silent heart abnormalities before they trigger strokes and other events, garnering interest from health insurers and pharma companies.

GOP senators' healthcare stabilization proposal would significantly cut premiums

A healthcare market stabilization proposal being promoted on Capitol Hill would cut individual plan premiums by an average of 10% next year, with those costs falling by 20% in 2020 and 2021, according to early estimates from congressional analysts.

US tax reform fires up healthcare M&A, buyback activity early in 2018

In the wake of the windfall brought forth by U.S. tax reform, the healthcare industry has money to spend on M&A, research and development, and share repurchasing programs.

White House panel: Urgent steps needed to lower cancer drug prices

The U.S. must take immediate, bipartisan and multilateral action to address the high costs of cancer drugs and deem the effort a national priority, a panel of White House advisers told President Donald Trump in a new report.

With HIV trends shifting, drugmakers look to boost diversity in research

Diversity was the key theme at an annual meeting of HIV researchers in Boston, where participants presented trials for the latest medicines alongside studies showing race- and gender-related infection and treatment trends.

US FDA to probe drug ads to evaluate need for more targeted risk disclosures

In an effort to better understand if patients and doctors are benefiting from the FDA's policies over drug companies' promotions of their prescription medicines, the agency is undertaking new social science research.

Regeneron, Sanofi: New data, price plan on cholesterol med put onus on payers

Executives from both companies said it is up to the payers to improve access to Praluent, following the Odyssey trial findings and the drugmakers' promise to lower costs.

Amgen's cholesterol drug still blocked by payers, new study says

Only 35% of patient requests for Amgen Inc.'s Repatha and Regeneron Pharmaceuticals Inc. and Sanofi's Praluent were approved by commercially insured and Medicare health plans in 2016, according to a new Amgen-funded study.